Abstract | BACKGROUND: METHODS: Using a liquid chromatography-tandem mass spectrometry method, urinary concentrations of 15 estrogen metabolites were determined in 77 prostate cancer cases, 77 healthy controls, and 37 subjects who had no evidence of prostate cancer after a prostate biopsy. RESULTS: We observed an inverse association between the urinary 16-ketoestradiol (16-KE2) and 17-epiestriol (17-epiE3)--metabolites with high estrogenic activity--and prostate cancer risk. Men in the lowest quartile of 16-KE2, had a 4.6-fold risk of prostate cancer (OR=4.62, 95% CI=1.34-15.99), compared with those in the highest quartile. CONCLUSIONS:
|
Authors | Ourania Kosti, Xia Xu, Timothy D Veenstra, Ann W Hsing, Lisa W Chu, Lenka Goldman, Ionut Bebu, Sean Collins, Anatoly Dritschilo, John H Lynch, Radoslav Goldman |
Journal | The Prostate
(Prostate)
Vol. 71
Issue 5
Pg. 507-16
(Apr 2011)
ISSN: 1097-0045 [Electronic] United States |
PMID | 20886539
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2010 Wiley-Liss, Inc. |
Chemical References |
- Biomarkers, Tumor
- Estrogens
|
Topics |
- Aged
- Biomarkers, Tumor
(urine)
- Case-Control Studies
- Chromatography, Liquid
- Estrogens
(urine)
- Humans
- Male
- Middle Aged
- Pilot Projects
- Prostatic Neoplasms
(urine)
- Statistics, Nonparametric
- Tandem Mass Spectrometry
|